Why researchers compare peptide suppliers

Peptide procurement is not commodity buying. Two vials labeled "retatrutide 10 mg" from two different vendors can differ by 5–10 percentage points in HPLC purity, an order of magnitude in endotoxin, and still both be "in spec" on a marketing page. The point of a real comparison is to look past marketing copy and evaluate the documentation and manufacturing behind the label.

This piece compares PX1 Research and PSPeptides on the criteria researchers actually use: manufacturing origin, purity documentation, endotoxin/sterility, catalog depth, lot traceability, packaging, and support.

Manufacturing and manufacturing origin

PX1 Research manufactures domestically in the United States in a facility operating under cGMP-aligned procedures. Every batch is manufactured, lyophilized, capped, and labeled in the same controlled workflow. That end-to-end control is why we can put a lot-specific COA (with chromatogram, mass spec, endotoxin, and Karl Fischer moisture) behind every product page.

PSPeptides publishes limited public information about where manufacturing occurs. Their documentation is available on request per product.

Why it matters for researchers: manufacturing origin drives your ability to trace a failed experiment back to a specific batch. If you cannot get lot-level chromatograms on demand, you cannot rule out purity as a variable.

Purity documentation

A modern research-grade peptide COA should include, at minimum:

• HPLC purity ≥98% with the actual chromatogram (not a redacted number)
• LC-MS or MALDI-TOF identity confirmation with expected vs observed mass
• Endotoxin by LAL, reported in EU/mg
• Sterility, appearance, and Karl Fischer moisture on lyophilized products

PX1 publishes chromatograms and mass spec traces for every lot at /purity-reports. PSPeptides publishes purity claims on product pages; chromatograms are available on request but are not indexed on the site.

Endotoxin and sterility

Endotoxin is the single most under-discussed variable in research peptides. High endotoxin will confound any inflammation, immune, or vascular endpoint even at HPLC purity ≥99%.

PX1 specifies <10 EU/mg on injectable-format peptides and publishes lot-specific LAL results. PSPeptides does not publish endotoxin as a routine catalog metric.

Catalog depth

PSPeptides has the broader retail SKU count. PX1 concentrates on GLP-family compounds (retatrutide, tirzepatide, semaglutide, cagrilintide, mazdutide), regenerative peptides (BPC-157, TB-500, KPV, GHK-Cu), mitochondrial (SS-31, MOTS-c, NAD+, urolithin), and higher-mass stacks. Fewer SKUs, higher batch scrutiny per SKU.

Lot traceability and packaging

PX1 vials ship with tamper-evident flip-off caps, lot number and manufacture date printed on-vial, and a scannable link back to the corresponding COA. PSPeptides ships standard labeled vials with lot numbers.

Shipping

Both suppliers ship domestically from the US. PX1 ships lyophilized product at ambient temperature with a stability window supporting standard ground transit; refrigerated ship options are available on request for temperature-sensitive stacks.

Where each is a better fit

• Choose PX1 when you need lot-level documentation without having to ask, endotoxin published as a standard metric, and end-to-end domestic manufacturing.
• Choose PSPeptides when catalog breadth (specifically longtail non-GLP SKUs) is the primary constraint.

The honest summary

PX1 competes on documentation quality per SKU rather than on catalog size. If you evaluate suppliers the way a QC chemist would — chromatogram, mass, endotoxin, moisture, packaging integrity — that is the axis we optimize for.

Research use only. Not for human consumption.